Comparison between YM099 and Captopril in Rats with Renal Mass Reduction-Induced Progressive Renal Disease(Pharmacology)
スポンサーリンク
概要
- 論文の詳細を見る
The effects of the ATP-sensitive potassium (K_<ATP>) channel opener YM099, and the angiotensin-converting enzyme (ACE) inhibitor captopril, on the progression of renal disease in rats with surgical renal mass reduction (RMR) were evaluated. Rats were subtotal (5/6) nephrectomized by resection of the renal poles. After 2 weeks of RMR, rats were randomized to three groups and treated for 6 weeks : no treatment (n=9) ; YM099 at a dose of 0.3mg/kg by daily oral administration (n=9) ; or captopril at a dose of 50mg/kg by daily oral administration (n=9). Sham-operated rats were used as normal animals (n=9). In RMR rats with no treatment, proteinuria progressively developed. At 8 weeks after RMR, renal function as assessed by plasma creatinine (Pcr) and blood urea nitrogen (BUN) was impaired. Pharmacological activation of K_<ATP> channel opening by YM099 showed no beneficial effect on proteinuria and renal functional parameters. On the other hand, pharmacological ACE inhibition by captopril significantly attenuated proteinuria, and tended to inhibit the increases in Per and BUN ; however, these effects were not statistically significant. The presents study indicates that YM099 exhibits no renoprotection with antiproteinuric effect in rats with progressive renal disease. These findings suggest that activation of K_<ATP> channel opening may play no role in the retardation of progressive renal disease.
- 公益社団法人日本薬学会の論文
- 2005-02-01
著者
-
UCHIDA Wataru
Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd.
-
Uchida W
Yamanouchi Pharmaceutical Co. Ltd. Ibaraki Jpn
-
Uchida Wataru
Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co. Ltd.
-
YATSU Takeyuki
Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd.
-
Yatsu Takeyuki
Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co. Ltd.
-
Inagaki Osamu
Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co.
-
AOKI Motonori
Institute for Drug Discovery Reserch, Yamanouchi Pharmaceutical Co., Ltd.
-
Aoki Motonori
Institute For Drug Discovery Research Yamanouchi Pharmaceutical Co. Ltd.
-
Yatsu T
Yamanouchi Pharmaceutical Co. Ltd. Ibaraki Jpn
関連論文
- Characterization of the Pharmacology of YM-198313 on Volume-Regulated Anion Channels(Pharmacology)
- Preparation of Highly Potent and Selective Non-Peptide Antagonists of the Arginine Vasopressin V_ Receptor by Introduction of a 2-Ethyl-1H-1-imidazolyl Group
- Novel Potassium Channel Activators : Synthesis and Structure-Activity Relationship Studies of 3,4-Dihydro-2H-1,4-benzoxazine Derivatives
- Synthetic Studies on Selective Type 4 Phosphodiesterase (PDE 4) Inhibitors. 1. Structure-Activity Relationships and Pharmacological Evaluation of 1,8-Naphthyridin-2(1H)-one Derivatives
- Studies on Nonpeptide Angiotensin II Receptor Antagonists. IV. Synthesis and Biological Evaluation of 4-Acrylamide-1H-imidazole Derivatives
- Studies on Nonpeptide Angiotensin II Receptor Antagonists. III. Synthesis and Biological Evaluation of 5-Alkylidene-3,5-dihydro-4H-imidazol-4-one-Derivatives
- Studies on Nonpeptide Angiotensin II Receptor Antagonists. II. Synthesis and Biological Evaluation of 5H-Pyrazolo[1,5-b][1,2,4]triazole Derivatives with a C-Linked Oxygen Functional Group at the 6-Position
- Studies no Nonpeptide Angiotensin II Receptor Antagonists. I. Synthesis and Biological Evaluation of Pyrazolo[1,5-b][1,2,4]triazole Derivatives with Alkyl Substituents
- 4-(3,4-Dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline Derivatives. II.Their Renal Vasodilation Activity and Structure-Activity Relationship
- Cardiovascular Effects of YM430,a 1,4-Dihydropyridine Derivative with β-Adrenoceptor Blocking Activity, in Dogs and Rats
- Comparison between YM099 and Captopril in Rats with Renal Mass Reduction-Induced Progressive Renal Disease(Pharmacology)
- Novel Potassium Channel Activators. III. Synthesis and Pharmacological Evaluation of 3,4-Dihydro-2H-1,4-benzoxazine Derivatives : Modification at the 2 Position
- Hypotensive Effects of YM430, a 1 ,4 : Dihydropyridine Derivative, in Spontaneously Hypertensive Rats and Renal Hypertensive Dogs
- Nonpeptide Arginine Vasopressin Antagonists for Both V_ and V_2 Receptors : Synthesis and Pharmacological Properties of 4'-(1,4,5,6-Tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanilide Derivatives and 4'-(5,6-Dihydro-4H-thiazolo[5,4-d][1]ben
- Nonpeptide Arginine Vasopressin Antagonists for Both V_ and V_2 Receptors : Synthesis and Pharmacological Properties of 2-Phenyl-4'-(2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-1-carbonyl)benzanilide Derivatives
- Preparation of Non-peptide, Highly Potent and Selective Antagonists of Arginine Vasopressin V_ Receptor by Introduction of Alkoxy Groups
- Highly Potent and Orally Active Non-Peptide Arginine Vasopressin Antagonists for Both V_ and V_2 Receptors : Synthesis and Pharmacological Properties of 4'-[(4,4-Difluoro-5-methylidene-2,3,4,5-tetrahydro-1H-1-benzoazepin-1-yl)carbonyl]-2-phenylbenzani
- Nonpeptide Arginine Vasopressin Antagonists for Both V_ and V_2 Receptors : Synthesis and Pharmacological Properties of 2-Phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanilide Derivatives
- Nonpeptide Arginine Vasopressin Antagonists for Both V_ and V_2 Receptors : Synthesis and Pharmacological Properties of 4'-[5-(Substituted Methylidene)-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl]benzanilide and 4'-[5-(Substituted Methyl)-2,3-dihy
- Effects of YM358,an Angiotensin II Type 1 (AT_1) Receptor Antagonist, and Enalapril on Blood Pressure and Vasoconstriction in Two Renal Hypertension Models
- In Vitro and in Vivo Vasodilatory Activity of barnidipine and Its Enantiomers
- Effects of Angiotensin II Type 1 Receptor Antagonist, YM358, on Cardiac Hypertrophy and Dysfunction after Myocardial Infarction in Rats
- Comparison of the Angiotensin II Type 1-Receptor Antagonist YM358 and the Angiotensin-Converting Enzyme Inhibitor Enalapril in Rats With Cardiac Volume Overload
- Antihypertensive Effect of YM730, A New Calcium Antagonist, in Stroke-prone Spontaneously Hypertensive Rats